TKNO Q2 2024 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M-16.6% YoY

Gross Profit

$3M29.2% margin

Operating Income

-$5M-53.0% margin

Net Income

-$5M-55.8% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+3.5%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$115M

Total Liabilities

$36M

Stockholders' Equity

$79M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$12M	-16.6%
Gross Profit	$3M	$5M	-44.7%
Operating Income	-$5M	-$7M	+27.1%
Net Income	-$5M	-$7M	+25.0%

Revenue Segments

Lab Essentials

$8M79%

Clinical Solutions

$2M16%

Other Product

$411,0004%

Geographic Segments

UNITED STATES

$9M96%

Non-US

$386,0004%